Immuno-oncology is a way to treat cancer by using the body’s immune system. BiTE (bispecific T-cell engager) technology is a targeted immuno-oncology platform that binds a patient’s own T cells to cancer cells. Because BiTE technology is flexible, it is easy to make molecules that attack tumor-specific antigens, which makes immuno-oncotherapy possible. Blinatumomab was the first standard BiTE molecule to be approved. It targets CD19 surface antigens on B cells and is mostly unaffected by genetic changes or escape mechanisms inside cells. More BiTE molecules are being made to treat other blood cancers (like multiple myeloma, acute myeloid leukaemia, and B-cell Hodgkin dışı lenfoma) and solid tumours (like prostate cancer, glioblastoma, stomach cancer, and small-cell lung cancer). BiTE molecules that have a longer half-life than the standard ones are also being made. With BiTE technology, advances in immuno-oncology could make it easier to treat both blood and solid tumours and make them more effective when used with other treatments.
BiTe tedavisi nedir?
Immuno-oncology therapies are scientifically proven ways to treat different types of solid and kan kanserleri. Hematologic cancers are a good fit for treatments that target the immune system because cancerous blood cells move around with immune cells. Several immünoterapi kanser tedavileri iş başında.
Monoclonal antibody checkpoint inhibitors that stop the binding of checkpoint proteins (like PD-1 and CTLA-4) are useful against many types of cancer. They work well and are safe for many solid tumours, especially when they target PD-1. Non-small-cell lung, kidney, and bladder cancers have all been treated successfully with these drugs. But many people don’t react to checkpoint inhibitors or get sick again after taking them. Except for non-Hodgkin lenfoma, most results on hematologic cancers have been disappointing, especially for myeloma and leukaemia, where the overall response rate in approved indications ranges from 12.0% to 48.5%.8-15.
Other immuno-oncology treatments, on the other hand, have a higher success rate. Chimeric antigen-receptor (CAR) T-cell therapies change a patient’s T cells to attack a specific cellular antigen, such as CD19 in the treatment of B-cell malignancies and B-cell maturation antigen (BCMA) in the treatment of multipl miyelom (MM). CAR T-cell treatments have shown promise in treating hematologic cancers. They haven’t been as effective in treating solid tumours, but there have been some good results with nöroblastom, human epidermal growth factor receptor tumours, and non-small-cell lung cancer. The genetic modification and in vitro multiplication of T cells take a long and complicated manufacturing process. This is a downside of this therapy because it makes it harder for patients to get this treatment quickly and in large numbers. The fact that lymphodepletion through chemotherapy preparation must be done first as a requirement for improved effectiveness is also a drawback.
BiTE (bispesifik T-hücre angaje edici) terapileri, bir hastanın kendi T hücrelerini tümör eksprese eden antijenlere bağlar. Bu, hastanın kendi T hücrelerinin, T hücrelerinin genlerini değiştirmeden veya onları vücut dışında büyütmeye veya manipüle etmeye ihtiyaç duymadan kanseri öldürme sitotoksik yeteneğini açar. BiTE molekülleri tek başına ilaç olarak veya daha etkili hale getirmek için diğer tedavilerle birlikte kullanılabilir.
BiTe etki mekanizması
BiTE molecules are antibody constructs with two binding domains. One recognises tumor-expressed antigens (such as BCMA, CD19, or -like protein [DLL3]), and the other, CD3, recognises T cells (Fig. 1). Two single-chain variable fragment (scFv) regions from monoclonal antibodies are connected by a flexible peptide linker to make the binding domains. The first scFv binding region can be changed to target any surface antigen, so it can be used right away to treat a wide range of tumours and can be used again later. The second scFv binding region always binds to CD3, which is a part of the T-cell receptor complex that never changes. When a BiTE molecule interacts with both a cytotoxic T cell and a tumour cell, the T cells begin to multiply. This increases the amount of effector cells and makes BiTE therapy more effective. Then, the death of cancer cells is started. BiTE molecules can get any T cells to do this because they don’t need co-stimulation or the usual processes of the major histocompatibility complex.
Blinatumomab is the first and only BiTE therapy that has been approved. It targets the CD19 receptor on both normal and cancerous B cells. It is a highly potent molecule with cytotoxic effects seen at low exposures (10–100 pg/mL)26. In its presence, T cells can perform serial-target lysis, quickly binding to and killing many cells. This is how BiTE therapies work, and it can be seen in other BiTE molecules that are still in research. In akut lenfoblastik lösemi (ALL), blinatumomab has been shown to be effective and safe. In 2014, the US Food and Drug Administration gave it fast approval, and in 2017, it got full approval for relapsed or refractory (R/R) B-cell precursor (BCP) ALL. In 2018, accelerated approval was given to blinatumomab for treating BCP-ALL with minimum residual disease (MRD). This was the first approval for this use. In November 2015, the European Medicines Agency also gave it a green light for BCP-ALL with a Philadelphia chromosome (Ph) that is negative and R/R. Blinatumomab is approved for R/R BCP-ALL in adults and children in 57 countries, including Japan, all countries in the European Union, Canada, and Australia.
BCP-ALL hastalarının tedavisi için Blinatumomab
Blinatumomab, BCP-ALL'nin tedavi edilme şeklini değiştirmiştir. Bakım standardı (SOC) kemoterapisine kıyasla, genel sağkalımı (OS) artırdı ve belirli yan etkilerin (AE'ler) sayısını azalttı. Randomize kontrollü çalışmalar da dahil olmak üzere birçok önemli çalışma, blinatumomab'ın güvenli olduğunu ve hem yetişkinlerde hem de çocuklarda BCP-ALL için çalıştığını göstermiştir. CAR T hücre tedavisi2 çocuğun (01626495-01029366 yaş) ve 25 yetişkinin (5-22 yaş) R/R BCP-ALL ve T-cell ALL ile tedavi edildiği 5 tek kollu çalışmanın (clinicaltrials.gov ID'leri NCT26 ve NCT60) yalnızca verileri vardır. Ancak sonuçlar ümit vericidir (%90'da tam yanıt [CR], %6'de 67 aylık olaysız sağkalım ile sürekli remisyon ve %78'lik genel sağkalım [OS] oranı [medyan takip, 7 ay; aralık, 1-24 ay]).
The TOWER study (A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-Precursor ALL; clinicaltrials.gov identifier NCT02013167) compared the effects of blinatumomab monotherapy against SOC chemotherapy in heavily pretreated adults with Ph-negative, R/R BCP-ALL. İnsanlar daha uzun yaşadıkları için çalışma erken durduruldu. Blinatumomab grubundaki AE'ler, daha önceki çalışmalarda görülenlerle aynıydı ve blinatumomab, SOC'ye göre daha düşük maruziyete göre ayarlanmış AE oranlarına sahipti.34 Blinatumomab, Ph-pozitif, R/R BCP-ALL olan kişiler ve Ph-negatif, R/R BCP-ALL olan çocuklar için de çalışır.
30% to 50% of people with BCP-ALL in complete hematologic remission show persistent MRD. In the single-arm, phase 2 BLAST study (A Confirmatory Multicenter, Single-Arm Study to Assess the Efficacy, Safety, and Tolerability of the BiTE Antibody Blinatumomab in Adult Patients With MRD of B-Precursor Acute Lymphoblastic Leukaemia; clinicaltrials.gov identifier NCT01207388), blinatumomab was tested on patients with BCP-ALL in first or later complete After blinatumomab treatment, 78% of patients who were MRD positive became MRD negative. The 5-year OS study showed a median OS of 36.5 months, and more than half of those who had a complete MRD response after the first cycle of blinatumomab were still alive at 5 years, which suggests that the treatment might be able to cure some patients. AEs were seen that were linked to sitokin salınım sendromu (CRS).31 Other studies, like NCT03023878 and NCT03340766, are still looking at blinatumomab in first-line settings and in combination with other treatments.
CD19-targeted treatments have been linked to failure because of the loss of CD19 antigen after treatment. The failure rates for blinatumomab range from 8% to 35%, and for CAR T hücre tedavileri, they range from 39% to 65%.36-40 We don’t fully understand what causes therapy to fail, but one possibility is immunoediting, in which antigen loss is caused by a T-cell-dependent process called immunoselection, which lets tumour cells get away.41 Lineage switch and epitope loss under therapy pressure have also been suggested as ways for tumours to escape treatment. However, a recent study on epitope loss found that some CD19 isoforms that help CAR T-cells escape were already present at the time of diagnosis. This suggests that combining treatments might be helpful. Another thing that can cause immunotherapy to fail is called “inhibitory T-cell signalling.” In this case, the blocking programmed death ligand-1 (PD-L1) is interesting because it is more common in B-cell ALL cells from patients who don’t respond to blinatumomab and can make CD3 BiTE molecules less effective.43 By making a CD28/PD-L1 BiTE that triggers the CD28 co-stimulatory signal instead of the inhibitory signaling pathway that is usually seen when a T cell binds to a PD-L1-expressing cancer cell, this inhibition could be turned off.43 Dual-targeted CAR T cells are also being looked into as a way to make up for the loss of tumour antigens. This can be done by modifying each T cell with 2 CAR molecules and 2 different binding domains (dual-signaling CAR) or by putting 2 different binding domains on 1 CAR molecule at the same time (TanCAR).
BiTE ve yönetimi ile olumsuz olaylar
Blinatumomab ile yapılan klinik çalışmalarda en yaygın yan etkiler ateş, düşük beyaz küre sayısı ve düşük trombosit sayısıdır. En önemli risklerden bazıları KRS, nörotoksisite ve ilaç hatalarıdır. Nörotoksisite, CD19'a özgü CAR T hücre tedavilerinde de olabilir, ancak bunun nedeni CD19 olmayabilir. CD1/CD1 hedefleri hakkında halen devam etmekte olan bir faz 20/3b çalışmasının sonuçları, 3. derece veya daha yüksek CNS AE'lerinin nadir olduğunu göstermiştir (tüm 3. derece AE'lerin %3'ü). Çoğu zaman, blinatumomab'ın CRS'ye tepkisi hafiftir, ancak nadir vakalarda şiddetli ve hatta yaşamı tehdit edici olabilir. Enflamatuar reaksiyonlar kortikosteroidlerle azaltılabilir. KRS şansını azaltmak için, ilk blinatumomab dozundan önce prednizon veya deksametazon infüzyonu vermek ve dozu yavaşça artırmak en iyisidir. Diğer BiTE moleküllerinden önce kortikosteroidlerin bu şekilde kullanılması, diğer BiTE molekülleri kullanılırken deksametazonun premedikasyon olarak kullanılmasına neden olmuştur. Ancak, bu etkinin tüm BiTE platformuna uygulanıp uygulanamayacağı net değil ve CRS ile başa çıkmanın başka yolları araştırılıyor. İnterlökin 6, KRS'ye neden olan ve buna sahip kişilerde yüksek olan bir sitokindir. İnterlökin-6 reseptörünü bloke eden tosilizumab, CAR T-hücresi tedavisinden sonra çok kötü seyreden KRS'yi tedavi etmek için kullanılmıştır.49 Hastanede, KRS'yi tedavi etmek için tümör nekroz faktörü inhibitörleri de kullanılmıştır.
